This IMC assay uses a panel of 33 antibodies that allows for the quantification of key cell types including pancreatic exocrine cells, islet cells, immune cells, and stromal components. The assay was applied to 12 pancreata obtained from donors with clinically diagnosed T1D and 6 pancreata from non-diabetic controls. In the pancreata from donors with T1D, it could visualize significant alterations in islet architecture, endocrine cell composition, and immune cell presentation. The IMC assay can be used to investigate complex events on the cellular level that will provide new insights on the pathophysiology of T1D.